IFNG positive signature

News alerts, weekly reports and conference planners

IFNG positive signature	Bladder Cancer	IFNG positive signature	Bladder Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3
IFNG positive signature	Non Small Cell Lung Cancer	IFNG positive signature	Non Small Cell Lung Cancer	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3	durvalumab Sensitive: C3 – Early Trials durvalumab Sensitive : C3

Associations